BETHESDA, Md.--(BUSINESS WIRE)--BrainScope Company, Inc., a privately held neurotechnology company with an initial focus on traumatic brain injury (TBI) and concussion assessment, announced today a series of executive appointments designed to build upon the company’s strong progress. The appointments include: Dr. Leslie Prichep, hired as Chief Scientific Officer; Kerstin Schultz, hired as President and Chief Operating Officer; Laurie Silver, promoted to Chief Financial Officer; and Angad Singh, hired as Chief Technology Officer.
“These additions to our leadership team will help us build upon the positive momentum that we have established over the last several years,” said Michael Singer, Chief Executive Officer of BrainScope. In the past year, BrainScope has achieved the following:
- Two FDA Clearances received
- $16 million of additional Department of Defense contracts awarded
- Further funding from GE and the NFL awarded as a final winner in the Head Health Challenge I
- Six additional articles published in the peer-reviewed literature
- Eleven new domestic and international patents issued
- Clinical studies conducted in twelve hospital Emergency Departments sites across the United States and abroad
- High school sports concussion study completed in conjunction with the Purdue Neurotrauma Group through the first phase of the GE NFL Head Health Challenge
- Continued investment received from private investors
“We are ready to take the next step forward by adding substantial depth and expertise to our management team as we look to commercialize and sell our products in the near future,” stated Singer.
The biographies of the four executives are as follows:
Leslie Prichep, Ph.D., Chief Scientific Officer
Until early 2015 Dr. Prichep was the Director of the Brain Research Laboratories and Professor of Psychiatry at the New York University School of Medicine, where she remains an Adjunct Professor. She has over 30 years of experience and recognition as a pioneer in the field of quantitative electrophysiology, clinically applied translational research, source localization and multivariate classification methodologies. She was responsible for the direction of the largest existing database of quantitative electrophysiological data from normal subjects and neuropsychiatric patients, which includes traumatic brain injury, post-concussion syndrome, PTSD and dementia patients. Dr. Prichep has over 125 publications, with another 55 book chapters, books, published proceedings and monographs, holds a number of patents and is considered one of the preeminent research scientists in the field of computerized electrophysiology. Dr. Prichep has been working with BrainScope since its inception.
Kerstin Schultz, President and Chief Operating Officer
Kerstin Schultz is a 25-year healthcare industry veteran, where she most recently held the position of Vice President of Global Project Management at Allergan. Prior to joining Allergan, Ms. Schultz held a number of positions at Baxter Healthcare, including Vice President of Portfolio and Project Management for the IV Therapy business, Vice President of Strategy for the global parenteral nutrition business, and Vice President of Strategy and R&D Portfolio Management. Before joining Baxter, Ms. Schultz was a management consultant with A.T. Kearney’s pharmaceutical and healthcare practice. Prior to A.T. Kearney, she was at Searle Pharmaceuticals (now Pfizer) for over 10 years, where she focused on both operational and strategic analytics, as well as driving decision quality. Ms. Schultz received her MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and her law degree from the School of Economics and Legal Science at the University of Gothenburg, Sweden.
Laurie Silver, Chief Financial Officer
Laurie Silver has over 20 years’ experience with a financial, accounting, strategic planning and operations background. Prior to BrainScope, she served as Director of Mergers and Acquisitions for the Services group at Symantec, where she led the integration of the Services organizations upon the $13 billion merger of Symantec and Veritas, which was the largest software company merger in history. Prior to Symantec, Ms. Silver was the Vice President of Finance and Administration of TrueCareers, a subsidiary of Sallie Mae; Manager of Financial Planning and Analysis across all business units of ABC/Disney; and a Senior Auditor at Ernst & Young LLP in New York. Ms. Silver graduated from the Stephen M. Ross School of Business at the University of Michigan and earned a CPA license from the State of New York. She has been with BrainScope since 2009 and has been promoted to Chief Financial Officer.
Angad Singh, Chief Technology Officer
Angad Singh brings to BrainScope almost 20 years of product leadership and operations experience in the development and commercialization of ground-breaking medical products. Mr. Singh was most recently a key executive and technology expert at CardioMEMS, Inc., where he led the transition of their flagship Heart Failure sensor product from concept to commercialization. The product received FDA approval in May 2014 and CardioMEMS was subsequently acquired by St. Jude Medical. While at CardioMEMS, Mr. Singh also directed the development, scale-up, and commercialization of the EndoSure sensor for monitoring of Abdominal Aortic Aneurysms. Prior to CardioMEMS, Mr. Singh held technical and managerial positions at Microgen Systems, SONY Semiconductor, and the Berkeley Sensor and Actuator Center. Mr. Singh has a M.S. degree in Electrical Engineering and Applied Physics from Case Western Reserve University and a B.S. degree in Electrical Engineering from the Visvesvaraya National Institute of Technology, India.
BrainScope has been awarded more than $27 million of U.S. Department of Defense research contracts for the development of its TBI and concussion assessment technology and has received significant funding from private investors to accelerate its development efforts.
Results from clinical studies utilizing BrainScope’s technology have been independently published through 15 articles in leading peer-reviewed neurotrauma and emergency medicine journals, including Journal of Neurotrauma, Brain Injury, Academic Emergency Medicine, Journal of Head Trauma Rehabilitation, The American Journal of Emergency Medicine, and Military Medicine.
BrainScope holds 86 issued and pending patents related to its technology.
Backed by Revolution (created by AOL co-founder Steve Case), Shaman Ventures, ZG Ventures, State of Maryland Venture Fund, Brain Trust Accelerator Fund, and Difference Capital, BrainScope is a medical neurotechnology company that is developing a new generation of hand-held, easy-to-use, non-invasive instruments designed to aid medical professionals in rapidly and objectively assessing TBI. BrainScope devices in development are based on a proprietary technology platform, which integrates databases of brainwave recordings with advanced digital signal processing, sophisticated algorithms, miniaturized hardware and disposable headset sensors. BrainScope's unique devices are being created to meet a long-standing clinical need for improved early identification, staging and triage of head injured patients. BrainScope devices under development, including the Ahead 300 and the Ahead Concussion Assessment System, for assessment of traumatically-induced structural head injury and concussion are for investigational use only. For more information, please visit www.brainscope.com.